FHA
ADPT icon

Flagship Harbor Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Flagship Harbor Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50
Closed -$2K – 578
2020
Q3 		$2K Hold
50
– – ﹤0.01% 1696
2020
Q2 		$2K Buy
+50
New +$1.82K ﹤0.01% 1785

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Harbor Advisors's ADPT Position: Q4 2020 in Review

Flagship Harbor Advisors sold out of Adaptive Biotechnologies (ADPT) in Q4 2020, closing a stake of 50 shares — an estimated $2K sold.

Flagship Harbor Advisors first reported a position in ADPT in Q2 2020 and held it in 2 quarters. The position peaked at $2K in Q3 2020. 250 funds tracked by Wall St. Rank hold ADPT as of Q4 2020.

  • Flagship Harbor Advisors reported no remaining Adaptive Biotechnologies position as of Q4 2020 after selling out during the quarter.
  • Flagship Harbor Advisors sold 50 Adaptive Biotechnologies shares in Q4 2020, an estimated $2K.
  • Flagship Harbor Advisors first reported a position in Adaptive Biotechnologies in Q2 2020 and held it in 2 quarters.
  • Flagship Harbor Advisors's Adaptive Biotechnologies position peaked at $2K in Q3 2020.
  • 250 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2020.

Based on Flagship Harbor Advisors's 13F filing for Q4 2020, filed 8 Feb 2021.